Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)Marie Robert, Jaafar Bennouna, Marta Jarlier et al.|Oncology|2017Cited by 55
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trialMichel Ducreux, F. Viret, Charlotte Baey et al.|Digestive and Liver Disease|2014Cited by 8
Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4).Marie Robert, Marta Jarlier, Thierry Conroy et al.|Journal of Clinical Oncology|2014Cited by 5
Supplementary Material for: Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)Marie Robert, Jaafar Bennouna, Marta Jarlier et al.|INDIGO (University of Illinois at Chicago)|2017Cited by 0
Supplementary Material for: Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)Marie Robert, Jaafar Bennouna, Marta Jarlier et al.|Figshare|2017Cited by 0